Abstract:Introduction: Alzheimer's disease (AD) is the most common cause of dementia worldwide, making it a major public health issue. Anti-amyloid and anti-tau antibodies are the most advanced therapeutic approach at present. Three drugs (lecanemab, donanemab and aducanumab) are on track to be marketed in the coming months. In this systematic review, we review all Phase 2 and Phase 3 clinical trials conducted in this indication and the particularities of the molecules tested. Methods: The PubMed and ClinicalTrials.gov databases were searched through February 2023 for Phase 2 and 3 clinical trials involving passive anti-amyloid or anti-tau immunotherapies with published results. This review has been compiled in compliance with the PRISMA checklists. Results: Of the 165 studies found and after eliminating duplicates, 40 studies had their results published on PubMed and/or ClinicalTrials.gov. Eight anti-amyloid molecules and four anti-tau molecules were the subject of Phase 2 studies, seven anti-amyloids were the subject of Phase 3 trials, and two molecules were granted early marketing approval by the US Food and Drug Administration (FDA). The results were compiled in summary tables showing the primary endpoints used, results, age of the study population and specific adverse events for these molecules. Discussion: Passive immunotherapy in AD is largely dominated by anti-amyloid antibodies, which are more numerous and more advanced in the pipeline. Lecanemab, donanemab and aducanumab are distinguished by their relative efficacy in terms of cognitive and functional evaluation but also by a decrease in amyloid and tau proteins in the brain. These three molecules have in common that they bind to N-terminal ends of amyloid fibrils and plaques. The findings of their studies raise the question of which criteria to apply when choosing which patient will receive them when marketed, such as the apoliprotein E gene's fourth allele (APOE4) genetic status of patients. The large number of negative studies may also raise the question of the criteria for defining the disease and the possible interest in redefining it on biological grounds to offer a more personalized medicine to patients suffering from neurodegenerative diseases.

Amyloid-β-targeting Immunotherapies for Alzheimer's Disease

Alzheimer's Disease Immunotherapy: Current Strategies and Future Prospects

Immunotherapy for Alzheimer's Disease: Targeting Β-Amyloid and Beyond.

Immunotherapy for Alzheimer’s disease: targeting β-amyloid and beyond

Amyloid-Directed Antibodies: Past, Present, and Future

The Recent Updates of Therapeutic Approaches Against Aβ for the Treatment of Alzheimer's Disease

Amyloid-Beta Immunotherapy for the Prevention and Treatment of Alzheimer Disease: Lessons from Mice, Monkeys, and Humans

Amyloid-beta antibody treatment in Alzheimer's disease

Passive Anti-Amyloid Beta Immunotherapies in Alzheimer's Disease: From Mechanisms to Therapeutic Impact

New progress in active immunotherapy targeting to amyloid beta

Passive immunotherapy for Alzheimer's disease: challenges & future directions

New developments of clinical trial in immunotherapy for Alzheimer's disease.

Passive Anti-amyloid Beta Monoclonal Antibodies: Lessons Learned over Past 20 Years

Immunotherapy in Alzheimer's Disease: Current Status and Future Directions

Amyloid-β in Alzheimer's disease: Structure, toxicity, distribution, treatment, and prospects

Immunotherapies Targeting Amyloid and Tau Protein in Alzheimer's Disease: Should We Move Away from Diseases and Focus on Biological Targets? A Systematic Review and Expert Opinion

Regulation of beta‐amyloid for the treatment of Alzheimer's disease: Research progress of therapeutic strategies and bioactive compounds

Recent advances in tau-directed immunotherapy against Alzheimer’s disease: an overview of pre-clinical and clinical development

The Amyloid-Beta Clearance: From Molecular Targets to Glial and Neural Cells

Development of amyloid beta-directed antibodies against Alzheimer's disease: Twists and turns

Advances in Immunotherapies and Drug Development Prospect for Alzheimer's Disease